Polymeric carriers linked to nucleotide analogues via a phosphoramide
bond
    9.
    发明授权
    Polymeric carriers linked to nucleotide analogues via a phosphoramide bond 失效
    通过磷酰胺键与核苷酸类似物连接的聚合载体

    公开(公告)号:US5981507A

    公开(公告)日:1999-11-09

    申请号:US766597

    申请日:1996-12-12

    IPC分类号: A61K47/48 A01N43/04

    摘要: Novel compositions of nucleotide analog prodrugs for the treatment of viral infections and cancer are herein disclosed. The prodrugs have a biocompatible polymeric carrier conjugated to the nucleotide analog via an amino-phosphate linkage. The amino group is provided by the carrier, which either inherently possesses a primary amine, or is modified with reactive groups that incorporate the primary amine onto the carrier. The carrier can be a polyamino acid, a polyvinylic polymer, a polysaccharide or combinations thereof, such as polylysine, HPMA, dextran, hydroxyethyl starch, or polyethylene glycol; the nucleotide analog can be ribavirin araA, AZT, acyclovir, 5-FUDR, araC or ddI. Methods of treating a viral infection of cancer using these prodrugs are also disclosed. The prodrugs endow the nucleotide analogs with substantially enhanced therapeutic efficacy and reduces toxicity in comparison to the nucleotide analog alone.

    摘要翻译: 本文公开了用于治疗病毒感染和癌症的核苷酸类似物前药的新型组合物。 前药具有通过氨基 - 磷酸键连接至核苷酸类似物的生物相容性聚合物载体。 氨基由载体提供,其本身具有伯胺,或者由将伯胺掺入到载体上的反应性基团进行改性。 载体可以是聚氨基酸,聚乙烯基聚合物,多糖或其组合,例如聚赖氨酸,HPMA,葡聚糖,羟乙基淀粉或聚乙二醇; 核苷酸类似物可以是利巴韦林araA,AZT,阿昔洛韦,5-FUDR,araC或ddI。 还公开了使用这些前药治疗癌症病毒感染的方法。 与单独的核苷酸类似物相比,前药使核苷酸类似物具有显着增强的治疗功效并降低毒性。